Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 65.01Bです。
高配当
同社は高配当銘柄であり、最新の配当性向は46.40%です。
安定配当
同社は過去5年間にわたり継続的に配当を実施しており、最新の配当性向は46.40%です。
適正水準
同社の最新のPEは32.37で、過去3年間の水準と比較して適正圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は2.01B株で、前四半期比で0.52%減少しています。
ビル・スミードが保有
スター投資家ビル・スミードは本銘柄を2.47M株保有しています。